Small

Zacks Small Cap Analysis – ARWR: PALISADE Part 3 Outcomes Revealed in NEJM… – Go Well being Professional

by
Zacks Small Cap Analysis – ARWR: PALISADE Part 3 Outcomes Revealed in NEJM… – Go Well being Professional

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Enterprise Replace Part 3 PALISADE Outcomes Revealed in The New England Journal of Drugs On September 2, 2024, Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR) introduced outcomes for the Part 3 PALISADE trial of plozasiran in sufferers with familial chylomicronemia syndrome (FCS). The outcomes had been … Read more

Zacks Small Cap Analysis – ACHV: New Skipper on the Helm – Go Well being Professional

by
Zacks Small Cap Analysis – ACHV: New Skipper on the Helm – Go Well being Professional

By John Vandermosten, CFA NASDAQ:ACHV Obtain Life Sciences, Inc. (NASDAQ:ACHV) introduced a shift in its most senior ranks with Richard Stewart reassuming his position as CEO and Thomas King, taking up as Government Chairman. Richard Stewart had beforehand held the CEO position at Obtain altering the mantle of command to John Bencich in Fall of … Read more

Zacks Small Cap Analysis – SCLX Makes Transfer to Increase Shareholder Worth – Go Well being Professional

by

By Brad Sorensen, CFA NASDAQ:SCLX READ THE FULL SCLX RESEARCH REPORT Scilex Holding Firm (NASDAQ:SCLX) is a revenue-generating firm that’s centered on addressing one of many greatest points dealing with humanity in the present day—that of the overuse of opioids. Scilex is targeted on creating non-opioid ache administration merchandise that present the aid sufferers so … Read more

Zacks Small Cap Analysis – CTSO: CytoSorbents Potential for Excessive Margin Income Progress Helps Worth Goal of $4.00 – Go Well being Professional

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 2nd quarter 2024 outcomes on August thirteenth and the outcomes have been principally above our expectations. For the 2nd quarter of 2024, complete revenues elevated roughly 5.0% to $9.9 million. Complete product gross sales have been $8.8 million, a rise of … Read more

Zacks Small Cap Analysis – VNRX: Nu.Q Vet Check is now obtainable in 17 international locations. Value slicing continues in a plan to be money move impartial in 2025. Administration centered on signing licensing offers for Seize-PCR (human most cancers detection technique) and Nu.Q NET for sepsis. $7.0 million financing accomplished. – Go Well being Professional

by
Zacks Small Cap Analysis – VNRX: Nu.Q Vet Check is now obtainable in 17 international locations. Value slicing continues in a plan to be money move impartial in 2025. Administration centered on signing licensing offers for Seize-PCR (human most cancers detection technique) and Nu.Q NET for sepsis. .0 million financing accomplished. – Go Well being Professional

By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT OPERATIONAL UPDATES Administration is implementing a important value slicing program with the aim of making certain that Volition (NYSE:VNRX) is money move impartial in 2025. Value reductions taken throughout 1H 2024 resulted in a 15.9% decline in working bills. Value discount measures have … Read more

x